Capricor Therapeutics, Inc.(CAPR)

$6.29—

Chart

Capricor Therapeutics, Inc.(CAPR)

NASDAQ

$6.29—

Chart Studio

CAPR(CAPR)

CAPR

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.12

Nov 9, 2026 · Reports after close

Revenue Estimate

$42M

FY2030E EPS$1.36

Analyst Sentiment

Wall St. Consensus

Buy

10 analysts·Moderate coverage

Score

7 Buy (70%)3 Hold (30%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

770%

Hold

330%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$3.50

-44.4%

Consensus

$7.00

+11.3%

Bull

$7.00

+11.3%

12-Month Target Range10 analysts

$3.50$7.00$7.00

Current $6.29Consensus

Current Price

$6.29

Upside to Consensus

$0.71

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-26.72%

EPS—

FY2028

Rev+338.99%

EPS—

FY2029

Rev+57.48%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$92M	$67M	$295M	$464M	$484M
Low	$50M	$36M	$162M	$256M	$266M
High	$159M	$119M	$513M	$807M	$842M
EBITDA Avg	$-52M	$-38M	$-168M	$-264M	$-275M
Low	$-91M	$-68M	$-291M	$-459M	$-479M
High	$-29M	$-20M	$-92M	$-145M	$-152M
EBIT Avg	$-53M	$-39M	$-170M	$-268M	$-279M
Low	$-92M	$-69M	$-296M	$-466M	$-486M
High	$-29M	$-21M	$-94M	$-147M	$-154M
Net Income Avg	$-22M	$-103M	$-5M	$-2M	$63M
Low	$-116M	$-156M	$-106M	$-3M	$26M
High	$72M	$34M	$179M	$-628,200	$124M
EPS Avg	$-1.50	$-1.66	$-0.27	$-0.03	$1.36
Low	$-2.50	$-3.36	$-2.27	$-0.06	$0.57
High	$1.55	$0.73	$3.86	$-0.01	$2.67
Analysts (Rev / EPS)	5 / 7	7 / 8	5 / 5	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$42M	$51M	$3M	$5M	$6M	$8M
Low	$42M	$51M	$3M	$5M	$6M	$8M
High	$42M	$51M	$3M	$5M	$6M	$8M
EBITDA Avg	$-24M	$-29M	$-2M	$-3M	$-3M	$-4M
Low	$-24M	$-29M	$-2M	$-3M	$-3M	$-4M
High	$-24M	$-29M	$-2M	$-3M	$-3M	$-4M
EBIT Avg	$-24M	$-30M	$-2M	$-3M	$-3M	$-4M
Low	$-24M	$-30M	$-2M	$-3M	$-3M	$-4M
High	$-24M	$-30M	$-2M	$-3M	$-3M	$-4M
Net Income Avg	$-7M	$-29M	$-27M	$-25M	$-23M	$-22M
Low	$-9M	$-623M	$-27M	$-25M	$-23M	$-22M
High	$-5M	$151M	$-27M	$-25M	$-23M	$-22M
EPS Avg	$-0.12	$-0.50	$-0.47	$-0.43	$-0.39	$-0.38
Low	$-0.15	$-10.75	$-0.47	$-0.43	$-0.39	$-0.38
High	$-0.08	$2.61	$-0.47	$-0.43	$-0.39	$-0.38
Analysts (Rev / EPS)	5 / 6	5 / 6	4 / 2	4 / 2	4 / 2	4 / 2

Earnings Surprises

Recent Analyst Actions

Jul 29, 2026Cantor Fitzgerald

Capricor downgraded to Neutral from Overweight at Cantor Fitzgerald

Target:$3.50

-46.7%from $6.57

Jul 28, 2026Industrial Alliance Securities

Capricor Therapeutics downgraded to Neutral from Buy at Alliance Global

Target:$7.00

+0.1%from $7.00

Jul 27, 2026Roth Capital

Capricor Therapeutics downgraded to Neutral from Buy at Roth Capital

Target:$7.00

+0.1%from $7.00

May 15, 2026Roth Capital

Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital

Target:$38.00

+27.5%from $29.81

Mar 13, 2026Cantor Fitzgerald

Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald After Q4 Result

Target:$62.00

+85.5%from $33.42

Dec 15, 2025UBS

Capricor Therapeutics price target raised to $50 from $21 at B. Riley

Target:$50.00

+91.4%from $26.12

Dec 10, 2025Piper Sandler

Capricor Therapeutics price target raised to $45 from $20 at Piper Sandler

Target:$45.00

+64.4%from $27.38

Dec 8, 2025Oppenheimer

Capricor Therapeutics price target raised to $54 from $22 at Oppenheimer

Target:$54.00

+100.8%from $26.89

Dec 4, 2025Maxim Group

Capricor Therapeutics price target raised to $50 from $25 at Maxim

Target:$50.00

+98.6%from $25.18

Dec 3, 2025Industrial Alliance Securities

Capricor Therapeutics price target raised to $48 from $16 at Alliance Global

Target:$48.00

+72.7%from $27.79

Dec 3, 2025H.C. Wainwright

Capricor Therapeutics price target raised to $60 from $24 at H.C. Wainwright

Target:$60.00

+100.3%from $29.95

Nov 11, 2025Roth Capital

Capricor Therapeutics price target raised to $13 from $12 at Roth Capital

Target:$13.00

+109.7%from $6.20

Jul 11, 2025Piper Sandler

Capricor Therapeutics price target lowered to $20 from $43 at Piper Sandler

Target:$20.00

+161.1%from $7.66

Jul 11, 2025H.C. Wainwright

Capricor Therapeutics price target lowered to $24 from $77 at H.C. Wainwright

Target:$24.00

+214.1%from $7.64

Oct 21, 2024Piper Sandler

Piper Sandler Starts Capricor Therapeutics (CAPR) at Overweight

Target:$35.00

+271.2%from $9.43

Oct 14, 2024Oppenheimer

Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR)

Target:$43.00

+383.7%from $8.89

Sep 25, 2024Maxim Group

Capricor Therapeutics price target raised to $25 from $12 at Maxim

Target:$25.00

+449.5%from $4.55

Sep 25, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)

Target:$40.00

+1338.8%from $2.78

Sep 17, 2024Oppenheimer

Capricor Therapeutics (CAPR) PT Raised to $15 at Oppenheimer

Target:$15.00

+490.6%from $2.54

May 16, 2024Oppenheimer

Oppenheimer Starts Capricor Therapeutics (CAPR) at Outperform

Target:$14.00

+396.5%from $2.82

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance